ChromoCure Set to Close $25,000,000+ Merger & Acquisition With Genome Research Group on the 10th of May, 2010
2010年4月22日 - 2:12AM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) - The Company scheduled the
formal closing of the merger and acquisition with Genome Research
Group for the 10th of May, 2010. The company will amalgamate with
GRG and integrate the Company's operations and assets with all GRG
Intellectual Property (IP) assets and operations.
The combined entity will possess complementary and leading edge
detection and therapeutic technology and protocols. Management
believes the transaction to be of significant long-term shareholder
value and furthers the Company's transition to research and
development and licensing as a source of significant long-term and
recurring revenues.
The updated financials will be prepared and timely posted as
part of the transaction.
The transaction is valued in excess of $25,000,000 and results
in significant increases to shareholder equity and reductions in
long-term liabilities. GRG management will assume management
control of the new entity and all current members of the ChromoCure
Board and executive management will step down as part of the
transaction. The Company intends to change its name to Genome
Research Group to properly reflect its new expanded operations. The
ChromoCure brand will continue to be used to promote the Company's
collaborative research initiatives.
Operations and assets include GRG's proprietary advanced
therapeutic modeling protocols and algorithms utilizing hypothermic
modulation and resonance. Included also is GRG's therapeutic
results and findings, methodologies and proprietary knowledge in
the non-toxic and non-invasive treatment of cancer.
GRG's advanced Therapeutic Modeling Protocols, together with
ChromoCure's landmark Chromosomal Scanning Technology, further
strengthens the Company's leadership in Cancer Detection, Therapy
and Cure by providing on-demand, real-time cancer progression
analysis to monitor and determine treatment efficacy; and puts new
impetus to its groundbreaking Project Boveri: Finding the Cure.
The Company had recently announced a Technology Exchange and
Collaboration Agreement with GRG, and through the initial
integration phase, determined that joining forces and merging
technology and operations would be of mutual benefit in advancement
of their shared objective; as a focused Cancer Therapy and Cure
Research & Development organization. The Company recently
announced its accelerated Therapy and Cure initiatives through the
launch of Project Boveri: Find the Cure; properly reflecting its
pioneering role in cancer detection, therapy and cure; and its
increased research programs and collaborations.
The Company will be completing its due diligence and will advise
in a timely fashion as to the progress of the completion of this
Letter of Intent and the details regarding the transaction.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection
systems and related therapeutic technologies. The Company's
proprietary CS200 Chromosomal Scanner has been proven accurate and
efficient in the measurement of the unique genomic characteristic
found in 100% of all cancers and never found in normal cells. The
Company's detection technology has an effective accuracy of 100%
for all cancers at all stages. The Company believes its technology
will become the worldwide gold standard for cancer detection,
progression measurement, and research for both therapy and cure.
The Company also applies its technology and knowledge to cancer
cure and therapeutics research.
Safe-Harbor Statement
This release contains statements or projections regarding future
performance that is forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those projected as a result of certain
risks and uncertainties. The company's filings contain various RISK
FACTORS (and are incorporated herein by reference) and should be
read before any investment decision.
ChromoCure, Inc. www.ChromoCure.com info@chromocure.com Tel
1.775.636.6548
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 5 2024 まで 6 2024
Chromocure (CE) (USOTC:KKUR)
過去 株価チャート
から 6 2023 まで 6 2024